Out For Tender

Out For TenderVerenigde StatenMedische apparatuur, farmaceutische artikelen en artikelen voor lichaamsverzorging

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Aanbestedende dienst
DEFENSE HEALTH AGENCY, Dept of Defense
Land
Verenigde Staten
Categorie
Medische apparatuur, farmaceutische artikelen en artikelen voor lichaamsverzorging
Sluitingsdatum
Sluit vandaag (24 Sep 2026 12:00 UTC-5)
Gepubliceerd
3 Sep 2026
Procedure
Solicitation - No Set aside used

Lees de officiële aankondiging en schrijf in → Inschrijven gebeurt altijd op het portaal van de aanbestedende dienst, nooit hier.

Wat de aanbestedende dienst vraagt

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Furoscix ReadyFlow – Diuretics – NA b. Gwyn Lo – Contraceptive Agents – Miscellaneous c. Jideytro – Lung Cancer – NA d. Omlyclo – Atopy – NA e. RizaFilm – Migraine Agents – NA f. Zenbexus – Multiple Myeloma – NA The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9403. Pre-Quotation Teleconference is on September 9, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

Taal van deze aankondiging: English. Titel en beschrijving tonen we precies zoals de aanbestedende dienst ze heeft gepubliceerd.

Source: SAM · reference HT9402-26-Q-9403 · JSON